Online citations, reference lists, and bibliographies.
← Back to Search

Apolipoprotein E In Alzheimer's Disease And Other Neurological Disorders

P. Verghese, Joseph M Castellano, D. Holtzman
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Apolipoprotein E (APOE) is a 299-aminoacid protein encoded by the APOE gene. Three common polymorphisms in the APOE gene, ɛ2, ɛ3, and ɛ4, result in a single aminoacid change in the APOE protein. APOE ɛ2, ɛ3, and ɛ4 alleles strongly alter, in a dose-dependent manner, the likelihood of developing Alzheimer's disease and cerebral amyloid angiopathy. In particular, APOE ɛ4 is associated with increased risk for Alzheimer's disease whereas APOE ɛ2 is associated with decreased risk. The effects of APOE genotype on risk of these diseases are likely to be mediated by differential effects of APOE on amyloid-β accumulation in the brain and its vasculature. Response to treatment for Alzheimer's disease might differ according to APOE genotype. Because convincing evidence ties the APOE genotype to risk of Alzheimer's disease and cerebral amyloid angiopathy, APOE has been studied in other neurological diseases. APOE ɛ4 is associated with poor outcome after traumatic brain injury and brain haemorrhage, although the mechanisms underlying these associations are unclear. The possibility that APOE has a role in these and other neurological diseases has been of great interest, but convincing associations have not yet emerged.
This paper references
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes.
V. Zannis (1982)
10.1161/01.STR.18.2.311
Cerebral amyloid angiopathy. A critical review.
H. Vinters (1987)
10.1126/SCIENCE.3283935
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.
R. Mahley (1988)
10.1016/0022-510X(89)90019-1
The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
D. Mann (1989)
10.1093/IJE/20.SUPPLEMENT_2.S28
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group.
J. Mortimer (1991)
10.1016/0006-8993(91)91092-F
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
Y. Namba (1991)
10.1016/0140-6736(91)92724-G
βA4 amyloid protein deposition in brain after head trauma
G. Roberts (1991)
10.1161/01.STR.23.11.1556
Lipoprotein and Apolipoprotein Profile in Men With Ischemic Stroke: Role of Lipoprotein (a), Triglyceride‐Rich Lipoproteins, and Apolipoprotein E Polymorphism
J. Pedro-Botet (1992)
10.1002/ANA.410330513
Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives
Richard Mayeux (1993)
10.1073/PNAS.90.5.1977
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
W. Strittmatter (1993)
10.1073/PNAS.90.20.9649
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.
D. Schmechel (1993)
10.1126/SCIENCE.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
A. M. Saunders (1993)
10.1016/S0140-6736(94)90691-2
The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease
P. Amouyel (1994)
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.
C. Harrington (1994)
10.1212/WNL.44.8.1513
Reduced apolipoprotein ϵ4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals
G. Rebeck (1994)
10.1016/S0140-6736(94)91208-4
Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases
V. Askanas (1994)
10.1016/0304-3940(94)91074-X
Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease
H. West (1994)
10.1016/0304-3940(94)90190-2
Senile dementia of the Lewy body type has an apolipoprotein E ε4 allele frequency intermediate between controls and Alzheimer's disease
J. Hardy (1994)
Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease.
H. L. West (1994)
10.1126/SCIENCE.8171342
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.
B. Nathan (1994)
Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
T. Wisniewski (1994)
Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals.
G. W. Rebeck (1994)
10.1038/372092A0
Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments
J. Ma (1994)
JM; for The French Research Group on Epidemiology of Human Spongiform Encephalopathies. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease
P Amouyel (1994)
10.1002/ANA.410380219
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Steven M. Greenberg (1995)
Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis.
S. Mui (1995)
10.1038/NM0295-135
Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury
J. Nicoll (1995)
10.1016/0304-3940(94)11108-U
Apolipoprotein E type ϵ4 allele frequency is not increased in patients with sporadic inclusion-body myositis
Charles R. Harringtonaa (1995)
10.1002/ANA.410380318
Apolipoprotein E ϵ4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis
S. Mui (1995)
10.1073/PNAS.92.8.3586
Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).
B. Hyman (1995)
10.1038/NM0995-852
ApoE as a prognostic factor for post–traumatic coma
S. Sorbi (1995)
Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury.
J. Nicoll (1995)
10.1212/WNL.45.3.555
Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease
R. Mayeux (1995)
10.1016/S0140-6736(95)91196-0
Apolipoprotein E in Creutzfeldt-Jakob disease
Yasushi Nakagawa (1995)
Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis.
C. Harrington (1995)
10.1002/ANA.410380215
A case—control study of apolipoprotein E genotypes in Alzheimer's disease associated with Down's syndrome
W. A. van Gool (1995)
10.1212/WNL.45.7.1323
Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease
E. Corder (1995)
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.
S. Greenberg (1995)
10.1056/NEJM199511093331902
Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein.
T. Polvikoski (1995)
10.1097/00002281-199511000-00005
New advances in the understanding of sporadic inclusion‐body myositis and hereditary inclusion‐body myopathies
V. Askanas (1995)
Apolipoprotein E and Alzheimer's disease
V. Fabian (1995)
10.1002/ANA.410380619
Apolipoprotein E ϵ4 in inclusion body myositis
M. Garlepp (1995)
10.1016/0304-3940(95)12030-8
Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease
M. Salvatore (1995)
10.1042/BJ3060599
Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E.
E. Castaño (1995)
10.1111/j.1749-6632.1996.tb32603.x
Apolipoprotein E Genotype and Gender Influence Response to Tacrine Therapy a
M. Farlow (1996)
10.1002/ANA.410390523
Lack of an association between apolipoprotein Eε4 and cerebral amyloid angiopathy in elderly japanese
M. Yamada (1996)
10.1212/WNL.47.1.190
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant
J. Olichney (1996)
Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks?
R. Katzman. (1996)
10.1002/(SICI)1097-4598(199612)19:12<1605::AID-MUS11>3.0.CO;2-Q
Apolipoprotein E allele frequencies in sporadic inclusion body myositis
S. Love (1996)
10.1002/ANA.410400608
Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies
M. Mirabella (1996)
Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
D. Premkumar (1996)
10.1001/ARCHNEUR.1996.00550120041014
Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease.
I. Zerr (1996)
10.1038/ng0996-55
Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides
M. Miyata (1996)
10.1007/978-3-7091-6892-9_14
Molecular biology of APO E alleles in Alzheimer's and non-Alzheimer's dementias.
C. Morris (1996)
10.1146/ANNUREV.MED.47.1.387
Apolipoprotein E alleles as risk factors in Alzheimer's disease.
A. Roses (1996)
Lack of an association between apolipoprotein E epsilon 4 and cerebral amyloid angiopathy in elderly Japanese.
M. Yamada (1996)
10.1016/0197-4580(96)00023-1
APOE alleles in Alzheimer's disease and vascular dementia in a population aged 85+
R. Sulkava (1996)
ects on cytotoxicity by oxidative insults and beta-amyloid peptides
J Pedro-Botet (1996)
10.1016/S0140-6736(97)04318-3
Association of apolipoprotein E polymorphism with outcome after head injury
G. Teasdale (1997)
10.1002/ANA.410410607
High frequency of apolipoprotein E ϵ2 Allele in hemorrhage due to cerebral amyloid angiopathy
J. Nicoll (1997)
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.
K. Bales (1997)
10.1001/JAMA.1997.03550020068040
Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing.
B. Jordan (1997)
10.1097/00005072-199804000-00008
Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels
N. Alonzo (1998)
10.1212/WNL.50.4.961
Association of apolipoprotein E ϵ2 and vasculopathy in cerebral amyloid angiopathy
S. Greenberg (1998)
10.1016/S0002-9440(10)65616-7
Cerebral Amyloid Angiopathy: Amyloid β Accumulates in Putative Interstitial Fluid Drainage Pathways in Alzheimer's Disease
R. Weller (1998)
10.1038/1206
APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease
M. Meyer (1998)
10.1212/WNL.50.3.669
Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
M. Farlow (1998)
10.1046/j.1471-4159.1998.70052070.x
Nascent Astrocyte Particles Differ from Lipoproteins in CSF
M. LaDu (1998)
10.1212/WNL.51.1.149
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
S. Craft (1998)
10.1073/PNAS.95.18.10914
Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females.
J. Raber (1998)
10.1212/WNL.52.2.244
Apolipoprotein E-ε4 genotype predicts a poor outcome in survivors of traumatic brain injury
G. Friedman (1999)
10.1073/PNAS.96.26.15233
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.
K. Bales (1999)
10.1523/JNEUROSCI.19-16-07100.1999
Truncated Apolipoprotein E (ApoE) Causes Increased Intracellular Calcium and May Mediate ApoE Neurotoxicity
M. Tolar (1999)
10.1038/22124
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
D. Schenk (1999)
10.1097/00005072-199909000-00008
Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig.
D. Smith (1999)
10.1136/jmg.36.2.108
Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length
P. Kehoe (1999)
10.1146/ANNUREV.GENOM.1.1.507
Apolipoprotein E: far more than a lipid transport protein.
R. Mahley (2000)
10.1192/bjp.176.5.468
APOE ε4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome
S. Deb (2000)
10.1073/PNAS.050004797
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.
D. Holtzman (2000)
10.1097/00006123-200009000-00026
Lower Cognitive Performance of Older Football Players Possessing Apolipoprotein E &egr;4
K. Kutner (2000)
10.1212/WNL.55.10.1536
Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation
S. Lichtman (2000)
10.1093/JNEN/59.9.751
Apolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses
A. Saunders (2000)
10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
D. Holtzman (2000)
10.1056/NEJM200008173430701
Patterns of brain activation in people at risk for Alzheimer's disease.
S. Bookheimer (2000)
10.1212/WNL.54.2.397
The association between APOE and dementia does not seem to be mediated by vascular factors
M. Prince (2000)
10.1038/78682
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F. Bard (2000)
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines
Fulco Ce (2000)
10.1001/ARCHNEUR.57.10.1480
Prospective study of apolipoprotein E genotype and functional outcome following ischemic stroke.
M. McCarron (2000)
10.17226/9953
Gulf War and Health
C. Fulco (2000)
10.1177/135245850000600403
Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate
P. Hùgh (2000)
uences the manifestation of Alzheimer’s disease in adults with Down’s syndrome
Y Namba (2000)
10.1016/S0022-510X(01)00569-X
Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis
V. Drory (2001)
10.1016/S0197-0186(01)00050-X
Apolipoprotein E and apolipoprotein E receptors modulate Aβ-induced glial neuroinflammatory responses
M. LaDu (2001)
Apolipoprotein E polymorphism and Alzheimer's disease.
Y. Yen (2001)
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
F. Fazekas (2001)
10.1212/WNL.57.5.853
Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis
F. Fazekas (2001)
10.1006/nbdi.2002.0483
Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease
A. Fagan (2002)
10.3171/JNS.2002.96.1.0090
Effect of apolipoprotein E genotype on hematoma volume after trauma.
I. Liaquat (2002)
10.1126/SCIENCE.1072994
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
J. Hardy (2002)
10.1176/APPI.AJP.159.5.738
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
G. Alexander (2002)
Apolipoprotein E ε 4 Modifies Alzheimer ’ s Disease Onset in an E 280 A PS 1 Kindred
P. Pástor (2003)
10.3233/JAD-2003-5206
Apolipoprotein E ε4 in an autopsy series of various dementing disorders
A. S. Nielsen (2003)
Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders.
A. S. Nielsen (2003)
10.1002/ana.10636
Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
P. Pastor (2003)
10.1001/ARCHNEUR.60.6.818
Increased risk of late posttraumatic seizures associated with inheritance of APOE epsilon4 allele.
R. Diaz-Arrastia (2003)
10.1097/00001756-200308060-00027
APOE and cerebral amyloid angiopathy in the elderly
S. Love (2003)
10.1034/j.1600-0404.2003.01365.x
Effect of apolipoprotein E genotype on in‐hospital mortality following intracerebral haemorrhage
M. McCarron (2003)
10.1055/S-2006-956754
Dementia with Lewy bodies.
I. McKeith (2003)
10.1073/pnas.2635903100
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
E. Reiman (2003)
[Assessment of apolipoprotein E genotype in Parkinson disease patients with and without dementia].
B. Jasińska-Myga (2004)
10.1016/j.jneuroim.2003.10.015
APOE genotype-specific differences in human and mouse macrophage nitric oxide production
C. Colton (2004)
10.1007/s10048-004-0193-0
Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis
Yi-Ju Li (2004)
10.1159/000076345
Apolipoprotein E Gene Polymorphism in Indian Patients with Alzheimer’s Disease and Vascular Dementia
K. Luthra (2004)
10.1007/S11883-004-0056-Z
Cardiovascular risk factors and Alzheimer’s disease
J. Luchsinger (2004)
10.1186/1742-2094-1-24
Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage
D. Wilcock (2004)
10.1212/01.WNL.0000130159.28215.6A
APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease
Xuemei Huang (2004)
10.1016/j.biopsych.2004.07.021
Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele
T. Sunderland (2004)
10.1212/01.WNL.0000128091.92139.0F
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
P. Tiraboschi (2004)
10.1001/ARCHPSYC.61.5.518
Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study
A. Khachaturian (2004)
10.1037/0882-7974.19.4.592
Apolipoprotein E and cognitive performance: a meta-analysis.
B. Small (2004)
10.1016/S0002-9440(10)63303-2
Long-Term Accumulation of Amyloid-β, β-Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma
X. Chen (2004)
10.1007/s00415-004-0508-y
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis
G. Savettieri (2004)
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.
Xiaohan Chen (2004)
10.1034/j.1600-0404.2003.00206.x
Apolipoprotein E polymorphism and neuropsychological outcome following subarachnoid haemorrhage
P. G. Morris (2004)
10.1523/JNEUROSCI.5170-04.2005
Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model
J. Fryer (2005)
10.1136/jnnp.2003.025528
Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype
P. Leclercq (2005)
10.1212/01.WNL.0000148478.39691.D3
Cerebral glucose metabolism in patients with AD and different APOE genotypes
A. Drzezga (2005)
Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.
M. Buttini (2005)
10.1097/01.ccx.0000155354.78617.91
Genetic influences on outcome following acute neurological insults
Ryan J. Waters (2005)
Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
B. D. Hoyt (2005)
10.1523/JNEUROSCI.1697-05.2005
β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
M. Buttini (2005)
10.1016/j.nbd.2004.10.013
Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology
C. Wang (2005)
10.1093/BRAIN/AWH595
The association between APOE ε4, age and outcome after head injury : a prospective cohort study
G. Teasdale (2005)
10.1016/j.nbd.2004.08.011
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1–42
B. Trommer (2005)
10.1194/JLR.M400486-JLR200
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400486-JLR200
R. Lane (2005)
10.1111/j.1468-1331.2004.00956.x
Association between APOE polymorphisms and mesial temporal lobe epilepsy with hippocampal sclerosis
S. N. Yeni (2005)
10.1212/01.WNL.0000156523.77347.B4
APOE influences vasospasm and cognition of noncomatose patients with subarachnoid hemorrhage
L. Lanterna (2005)
10.1038/nature04399
Role of cholesterol and lipid organization in disease
F. Maxfield (2005)
10.1001/ARCHNEUR.62.3.454
Individual Growth Curve Analysis of APOE ε4–Associated Cognitive Decline in Alzheimer Disease
B. Hoyt (2005)
10.1056/NEJMOA050151
Vitamin E and donepezil for the treatment of mild cognitive impairment.
R. Petersen (2005)
10.1038/sj.tpj.6500369
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease
M. E. Risner (2006)
10.1096/fasebj.20.9.1573-c
Aß peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
(2006)
10.1159/000095246
Apolipoprotein E ε4 Allele Is Associated with Vascular Dementia
L. Baum (2006)
10.1002/mds.20663
Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia
N. Pankratz (2006)
10.1111/j.1468-1331.2006.01360.x
The association between apolipoprotein E and multiple sclerosis
M. Pinholt (2006)
10.1136/jnnp.2006.097543
Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage
N. A. Martínez-González (2006)
10.1146/ANNUREV.NEURO.29.051605.112819
Brain work and brain imaging.
M. Raichle (2006)
10.1017/S1355617706060826
Working memory deficits in multiple sclerosis: Comparison between the n-back task and the Paced Auditory Serial Addition Test
B. Parmenter (2006)
10.1212/01.wnl.0000210531.19498.3f
APOE epsilon variation in multiple sclerosis susceptibility and disease severity
R. Burwick (2006)
10.1159/000092960
Apolipoprotein E υ4 Allele Frequency in Vascular Dementia
Y. Davidson (2006)
10.1016/J.TIBS.2006.06.008
Apolipoprotein E structure: insights into function.
D. Hatters (2006)
10.1159/000093867
A Study of Potential Interactive Genetic Factors in Huntington’s Disease
P. Panegyres (2006)
10.1016/j.neurobiolaging.2006.05.029
Occurrence and co-localization of amyloid β-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice
D. Thal (2007)
10.1159/000109998
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
B. Plassman (2007)
10.1001/ARCHNEUR.64.2.261
Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia.
B. Jasinska-Myga (2007)
10.1016/j.neulet.2006.12.008
Phenotypic associations of tau and ApoE in Parkinson's disease
S. Papapetropoulos (2007)
10.1385/JMN:23:3:205
A dual role for apolipoprotein E in neuroinflammation
L. Guo (2007)
10.1016/S1474-4422(07)70106-0
Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study
P. Shaw (2007)
10.1016/j.jalz.2007.04.381
Forecasting the global burden of Alzheimer’s disease
R. Brookmeyer (2007)
10.1212/01.wnl.0000253021.60887.db
ApoE-ε4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy
R. Busch (2007)
10.1016/j.nmd.2007.09.005
Apolipoprotein ε alleles in sporadic inclusion body myositis: A reappraisal
M. Needham (2008)
10.1089/neu.2007.0489
Meta-analysis of APOE4 allele and outcome after traumatic brain injury.
W. Zhou (2008)
10.1007/s00439-008-0564-y
Association between Apolipoprotein E genotype and cerebral palsy is not confirmed in a Caucasian population
G. McMichael (2008)
10.1038/nn2058
A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gilbert Gallardo (2008)
Apolipoproteína ε4 en la demencia con cuerpos de Lewy
F. C. García (2008)
10.1002/gps.2039
Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down Syndrome
V. Prasher (2008)
10.1016/j.neulet.2008.10.018
Lack of association of APOE and tau polymorphisms with dementia in Parkinson’s disease
M. Ezquerra (2008)
Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal.
M. Needham (2008)
10.1177/0891988707311028
Lack of Association Between Apolipoprotein E Polymorphism and Vascular Dementia in Koreans
Ki Woong Kim (2008)
[Apolipoprotein E4 in dementia with Lewy bodies].
F. Carrillo García (2008)
10.1016/S8756-5005(08)79111-X
Association of Apolipoprotein E Genotype and Cerebral Palsy in Children
R. Goldstein (2008)
10.1523/JNEUROSCI.4147-08.2008
Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice
J. Koenigsknecht-Talboo (2008)
10.1016/j.jns.2008.06.025
Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis
H. Zetterberg (2008)
10.1038/454418a
Alzheimer's disease: Moving towards a vaccine
D. Holtzman (2008)
10.1038/nature08538
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
R. Perrin (2009)
10.2741/3567
Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy.
S. Love (2009)
10.1073/pnas.0812697106
Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia
F. Agosta (2009)
10.1016/j.neurobiolaging.2007.07.024
ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain
V. V. Bandaru (2009)
10.1056/NEJMoa0809437
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.
R. Caselli (2009)
[Lipoproteins and their receptors in the central nervous system].
T. Miida (2009)
10.1016/S1053-8119(09)71381-3
Distinct patterns of brain activity in young carriers of the APOE e4 allele
N. Filippini (2009)
10.1146/annurev.clinpsy.032408.153625
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.
S. Bookheimer (2009)
10.1073/pnas.0900345106
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
E. Reiman (2009)
10.1212/WNL.0b013e3181c6784a
APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.
D. Kaufer (2009)
10.1016/j.neuroimage.2009.06.021
Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups
A. Fleisher (2009)
10.1097/NEN.0b013e3181a9d503
Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury
A. McKee (2009)
10.1016/j.neuron.2009.06.026
The Role of Apolipoprotein E in Alzheimer's Disease
Jungsu Kim (2009)
10.1212/WNL.0b013e3181c67808
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway (2009)
10.1523/JNEUROSCI.0887-09.2009
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
K. Bales (2009)
APOE ε 4 and bapineuzumab : infusing pharmacogenomics into Alzheimer disease therapeutics
D Kaufer (2009)
10.1016/j.neuropharm.2010.04.006
Biomarkers in translational research of Alzheimer’s Disease
R. Tarawneh (2010)
10.1212/WNL.0b013e3181ff94f7
APOE varepsilon2 and presymptomatic stage Alzheimer disease: how much is not enough?
R. Caselli (2010)
10.1212/WNL.0b013e3181ffe4d1
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects
G. C. Chiang (2010)
10.1002/ana.22134
Variants at APOE influence risk of deep and lobar intracerebral hemorrhage
A. Biffi (2010)
10.1159/000285166
Association between APOE ε4 Allele and Vascular Dementia: The Cache County Study
Yi-Fang Chuang (2010)
10.1523/JNEUROSCI.3987-10.2010
APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42
Y. Sheline (2010)
10.1159/000318845
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
M. Gold (2010)
10.2165/11310960-000000000-00000
Effects of Donepezil,Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer’s Disease
A. Santoro (2010)
10.1016/j.neuroimage.2009.07.025
Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging
E. Reiman (2010)
10.1212/WNL.0b013e3181e03844
A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE
D. Laskowitz (2010)
10.1212/WNL.0b013e3181e074a7
APOE ε4 and the cognitive genetics of multiple sclerosis
O. Ghaffar (2010)
10.1002/ana.21843
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
John C. Morris (2010)
10.1016/S1474-4422(09)70299-6
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
C. Jack (2010)
Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease
Y. Huang (2010)
10.1016/S0084-3954(09)79603-4
Longitudinal Modeling of Age-Related Memory Decline and the APOE ɛ4 Effect
J. Stockman (2011)
Lipoprotein and apolipoprotein profi le in men with ischemic
J Pedro-Botet



This paper is referenced by
10.1080/26896583.2021.1891825
Consequences of space radiation on the brain and cardiovascular system
C. M. Davis (2021)
10.1001/jamanetworkopen.2020.33012
Assessment of Advanced Glycation End Products and Receptors and the Risk of Dementia
Jinluan Chen (2021)
10.1016/j.neuropharm.2020.108342
Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease
Wen-Hui Ma (2021)
10.3389/fpsyg.2021.686036
Cognition in Patients With Memory Difficulties and Dementia Relative to APOE e4 Status
K. Hestad (2021)
10.1109/TBME.2021.3049199
A Graph Gaussian Embedding Method for Predicting Alzheimer's Disease Progression With MEG Brain Networks
Mengjia Xu (2021)
10.1111/ene.14870
Association of HMOX‐1 with sporadic Alzheimer’s disease in southern Han Chinese
Bei Zhang (2021)
10.1007/s00101-021-00972-1
Effects of Apolipoprotein Ε ε4 allele on early postoperative cognitive dysfunction after anesthesia
Deng-feng Ding (2021)
10.1038/s41536-020-00114-y
The genetic basis of inter-individual variation in recovery from traumatic brain injury
D. Côrtes (2021)
10.1007/s40263-020-00781-x
Intranasal Insulin for Alzheimer’s Disease
M. Hallschmid (2021)
10.1038/s41598-020-80892-z
Changes in retinal microvasculature and retinal layer thickness in association with apolipoprotein E genotype in Alzheimer’s disease
Joo Youn Shin (2021)
10.1038/s41582-021-00529-1
The human connectome in Alzheimer disease — relationship to biomarkers and genetics
Meichen Yu (2021)
10.1080/10705511.2020.1863154
Bayesian Causal Mediation Analysis with Latent Mediators and Survival Outcome
Rongqian Sun (2021)
10.1101/2021.07.13.452239
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Zengjie Xia (2021)
10.3389/fneur.2021.729184
Integrative Neuroinformatics for Precision Prognostication and Personalized Therapeutics in Moderate and Severe Traumatic Brain Injury
F. Zeiler (2021)
10.3233/jad-210695
White Matter Hyperintensities and Apolipoprotein E Affect the Association Between Mean Arterial Pressure and Objective and Subjective Cognitive Functioning in Older Adults.
Youjin Jung (2021)
10.3389/fmolb.2021.651215
Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer’s Disease
Jhana O. Hendrickx (2021)
10.1186/s40035-021-00237-2
COVID-19 and Alzheimer’s disease: how one crisis worsens the other
X. Xia (2021)
10.1038/s41380-021-01249-0
The Amyloid-β Pathway in Alzheimer’s Disease
H. Hampel (2021)
10.1186/s41065-021-00190-0
Bioinformatics analysis of differentially expressed genes and identification of an miRNA–mRNA network associated with entorhinal cortex and hippocampus in Alzheimer’s disease
Haoming Li (2021)
10.1186/s13195-021-00857-w
Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer’s disease
Jaeho Kim (2021)
10.1038/s41598-020-80909-7
Apolipoprotein E4 effects on topological brain network organization in mild cognitive impairment
Gretel Sanabria-Diaz (2021)
10.3390/md19040190
24(S)-Saringosterol Prevents Cognitive Decline in a Mouse Model for Alzheimer’s Disease
N. Martens (2021)
10.1007/s00401-021-02361-9
Apolipoprotein E regulates lipid metabolism and α-synuclein pathology in human iPSC-derived cerebral organoids
Jing Zhao (2021)
10.1016/j.conb.2021.02.001
APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention
Xiaopu Zhou (2021)
10.3390/ijms22094547
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Emilie W Kjeldsen (2021)
10.1007/S13273-021-00130-Z
Importance of GWAS in finding un-targeted genetic association of sporadic Alzheimer’s disease
Jaya Bagaria (2021)
10.1172/jci.insight.149227
The influence of ApoE4 on the clinical outcomes and pathophysiology of degenerative cervical myelopathy
Alexa Desimone (2021)
10.1016/j.neulet.2021.135627
Mini-Review: Is iron-mediated cell death (ferroptosis) an identical factor contributing to the pathogenesis of some neurodegenerative diseases?
A. Viktorínová (2021)
10.1111/jnc.15465
Mass spectrometry-based methods for robust measurement of Alzheimer's Disease biomarkers in biological fluids.
M. Korecka (2021)
10.3389/fcell.2021.716300
Hearing Loss in Neurological Disorders
Siyu Li (2021)
10.3389/fgene.2021.658323
Discovery and Validation of Key Biomarkers Based on Immune Infiltrates in Alzheimer’s Disease
Zhuohang Liu (2021)
10.1016/j.cca.2021.05.011
The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis.
K. Kirmess (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar